(NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
The month-long exercise, which will continue until June 28, was launched from Puri and covers all 147 Assembly constituencies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results